CATEGORY: Press Release

Aclarion Adds to Strong Patent Portfolio with New U.S. Patent Application

Strengthens portfolio by addressing the anaerobic bacteria that can seed into the intervertebral disc, proliferate, and accelerate painful disc degeneration. Successful commercialization of IP holds the promise of giving physicians better data to make the critical decision as to whether antibiotic therapy or surgery is the preferred treatment option.   December 01, 2022, Broomfield, CO […]

Dr. Sigurd Berven to join Aclarion as a Key Opinion Leader Surgeon Advisor

October 24, 2022, Broomfield, CO – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that Sigurd Berven M.D., Chief of Spine Service, Orthopaedic Surgery at University of California […]

Aclarion to Present at the LD Micro Main Event XV

Presentation on Tuesday, October 25th at 9:00 AM PT   Broomfield, CO, October 12, 2022 – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain (CLBP), announced today that it will […]

Aclarion Announces Participation at the NASS 37th Annual Meeting

Nociscan utilized within unprecedented NIH HEAL Initiative featured at NASS 2022 NociscanTM is the first evidence-supported SaaS platform to objectively analyze intradiscal pain Nociscan bridges major diagnostic void between MRI and provocative discography   October 10, 2022, Broomfield, CO – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is […]

John Keller M.D. to Join Aclarion as a Key Opinion Leader Surgeon Advisor

  Aclarion Key Opinion Leader program supports focused strategy of building strong clinical evidence and payer community advocacy to drive adoption of NociscanTM solution   October 3, 2022, Broomfield, CO – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help […]

Nociscan Selected for Inclusion in Pivotal National Institutes of Health (NIH) Study for Low Back Pain

NIH funded Biomarkers for Evaluating Spine Treatments (BEST) Trial launching this quarter BEST to study the role of biomarkers in optimizing the treatment of chronic low back pain Nociscan to be commercially active across seven participating major academic medical centers   September 19, 2022, Broomfield, CO – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, […]

Aclarion Announces Start of Healthcare Economic Analysis Study to Evaluate Financial Impact of Nociscan

Initial findings from the EVAL study are expected to be released in Q4 2022 Study initiated to assess impact of Nociscan on the cost of care for chronic low back pain (CLBP) patients Promising initial clinical evaluations with 87% of patients treated at discs identified as painful by Nociscan continuing to show significant clinical improvements […]

Aclarion to Present 2-year Follow-up Data Linking Nociscan to Better Surgical Outcomes

Superior Clinical Outcomes for NociscanTM Proving to be Durable at Two Years Two Year Results and the Schedule of Future Clinical Trials to be Outlined at the Annual State of Spine Surgery Think Tank 2022 San Mateo, CA –Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and […]

Aclarion, Inc. Announces Closing of $9.4 Million Initial Public Offering

SAN MATEO, CA, April 26, 2022 — Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), artificial intelligence and a proprietary biomarker to optimize clinical treatments for low back and neck pain, today announced the closing of its previously announced initial public offering of 2,165,000 […]

Aclarion, Inc. Announces Listing on Nasdaq and Pricing of $9.4 Million Initial Public Offering

SAN MATEO, CA, April 21, 2022 — Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), artificial intelligence and a proprietary biomarker to optimize clinical treatments for low back and neck pain, today announced the pricing of its initial public offering of 2,165,000 shares of […]

Request Info or Schedule a Demo

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

Aclarion
8181 Arista Place,
Suite 100
Broomfield, CO 80021

info@aclarion.com

833-ASK-ACON (833-275-2266)